Oncology Learning Center | Personalized Therapies for Lung, Breast, Colorectal, Hematology, Cancer

>> Login

>> New User Registration

March 11, 2010

Overview

Disclosure

Faculty

Agenda

Hotel Accommodations

Registration

Symposium Co-Chairs

Dennis J. Slamon, MD, PhD
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research
Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women’s Health Research and Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, CA

Lisa A. Carey, MD
Medical Director, UNC Breast Center
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Expert Faculty

Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Matthew J. C. Ellis, MB, BChir, PhD
Professor, Department of Medicine
Oncology Division
Medical Oncology Section
Washington University School of Medicine
St. Louis, MO

Judy E. Garber, MD, MPH
Director, Cancer Risk and Prevention Program
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Ana M. Gonzalez-Angulo, MD, MSc, FACP
Assistant Professor, Department of Breast Medical Oncology
Assistant Professor, Department of Systems Biology
Division of Cancer Medicine
The University of Texas
M. D. Anderson Cancer Center
Houston, TX

Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, NY
Co-Chair, Breast Committee,
The Cancer and Leukemia Group B (CALGB)

Kelly K. Hunt, MD, FACS
Professor of Surgery
Chief, Surgical Breast Section
Department of Surgical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Allan Lipton, MD
Professor of Medicine and Oncology
M. S. Hershey Medical Center
The Pennsylvania State University
Hershey, PA

C. Kent Osborne, MD
Director, Breast Center at Baylor College of Medicine
Director, Baylor Cancer Center
Professor of Medicine and Cellular and Structural Biology
Baylor Cancer Center
Houston, TX

Mark Pegram, MD
Professor of Medicine and Oncology
Director, Breast Cancer Program
University of Miami Cancer Center
Miami, FL

Lori J. Pierce, MD
Vice Provost for Academic and Faculty Affairs
Professor, Department of Radiation Oncology
University of Michigan
Ann Arbor MI

Lajos Pusztai, MD, DPhil
Professor of Medicine
Department of Breast Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Peter M. Ravdin, PhD, MD
Adjunct Professor of Medical Oncology
University of Texas at San Antonio
San Antonio, TX

George W. Sledge, Jr.,MD
Ballve-Lantero Professor
of Oncology and Pathology
Co-Director, Breast Cancer Program
Indiana University Cancer Center
Indianapolis, IN
Co-Chair, Breast Committee,
The Eastern Oncology Cooperative Group
(ECOG)
President, American Society of Clinical Oncology
(ASCO)

February 6, 2010 · La Jolla, CA

Hilton La Jolla Torrey Pines

Taught by the top academic experts in breast cancer this is THE symposium on breast cancer that you should attend in 2010. It contains the relevant data from the recent ASCO and SABCS. Personalized medicine for treating breast cancer is a reality. This symposium will help clinicians improve their selection of the most appropriate therapeutics, and will also help clinicians to identify the patient sub-populations of breast cancer who will respond to specific drug therapies.

CO-CHAIRS

Dennis J. Slamon, MD, PhD
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research
Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women's Health Research and Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, CA

Lisa A. Carey, MD
Medical Director, UNC Breast Center
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC


•	Overview
•	Educational Statement of Need
•	Disclosure
•	Target Audience
•	Learning Objectives
•	CME Credit Information
•	Agenda
•	Faculty
•	Hilton La Jolla Torrey Pines
•	Registration

Agenda

February 6, 2009 – Saturday
7:00AM - 7:50AM	Breakfast
7:00AM	Registration
8:00AM-8:10AM	Welcome and Introductions and CME Pre Test	Drs. Lisa Carey and Dennis Slamon

Session 1: Diagnosis and Molecular Classification of Breast Cancer for Personalizing Therapies – Session Chair: Peter Ravdin

8:10AM-8:40AM	Prognostic Profiling. In which patients with breast cancer are these prognostic gene expression arrays beneficial? What are the clinical applications of prognostic gene testing for breast cancer?	Lisa Carey
8:40AM-9:00AM	Predictive Profiling. In which patients with breast cancer are these predictive gene expression arrays beneficial? What are the clinical applications of predictive gene testing for breast cancer? What are the molecular predictors of response to adjuvant endocrine therapy?	Matthew Ellis
9:00AM - 9:20AM	Point-CounterPoint #1: Genomic profiling assay tests should be done for clinical decision making for node-positive breast cancer.	YES: Lajos Pusztai NO: Lisa Carey
9:20AM - 9:40AM	How do the molecular tests we use help us with clinical decision making for treating our patients with breast cancer?	Peter Ravdin
9:40AM - 9:50AM	Session 1 Case Study – The learners select treatment options using the ARS handsets.	Lajos Pusztai
9:50AM - 10:10AM	Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session: Is any of this a new standard of care? Should it be discussed with your patients? How can it be applied in the clinic today? Each faculty member addresses all three consensus-building questions.	Discussant Leader: Peter Ravdin Session 1 Faculty and Audience
10:10AM - 10:30AM	BREAK	EXHIBITS

Session 2: Local-Regional Control for Breast Cancer Patients - Session Chair: Lori Pierce

10:30AM - 10:50AM	Personalizing surgical therapy and best clinical practices for breast cancer patients	Kelly Hunt
10:50AM - 11:10AM	Personalizing radiation therapy and best clinical practices for breast cancer patients	Lori Pierce
11:10AM - 11:20AM	Session 2 Case Study – The learners select treatment options using the ARS handsets	Kelly Hunt
11:20AM - 11:35AM	Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session: Is any of this a new standard of care? Should it be discussed with your patients? How can it be applied in the clinic today? Each faculty member addresses all three consensus-building questions.	Discussant Leader: Lori Pierce Session 2 Faculty and Audience
11:35AM - 12:40PM	Lunch with the Professors, and, Exhibits	All Attendees

Session 3: Current Clinical Applications of Personalized Therapies and Best Clinical Practices for the Three Major Sub Types of Breast Cancer in both the Adjuvant and Metastatic settings - Session Chair: Mark Pegram

12:40PM-1:00PM	Point-CounterPoint #2 Based upon the RIBBON One and Two trials' data bevacizumab should be included in any first-line therapy regimen with chemotherapy.	YES: George Sledge NO: Clifford Hudis
1:00PM - 1:20PM	HER2-positive disease - Personalizing therapies with best clinical practices. State-of-the-Art Therapies	Dennis Slamon
1:20PM - 1:40PM	HER2-resistant breast cancer - How do we best manage these patients? Do we use different tests? Do we use different systemic therapies?	Mark Pegram
1:40PM - 2:00PM	Point-CounterPoint #3: Adjuvant trastuzumab should be administered to patients with stage I breast cancers that are small, node-negative tumors.	YES: Ana Gonzalez-Angulo NO: Lisa Carey
2:00PM - 2:20PM	ER/PR-positive disease - Personalizing therapies with best clinical practices for adjuvant therapy, primary therapy and for resistant disease.	C. Kent Osborne
2:20PM - 2:40PM	Triple-negative-resistant breast cancer - How do we best manage these patients? Do we use different tests? Do we use different systemic therapies?	Judy Garber
2:40PM - 3:00PM	Point-CounterPoint #4: All high-risk patients with breast cancer should receive anthracycline therapy.	YES: Harold Burstein NO: Dennis Slamon
3:00PM - 3:15PM	BREAK	EXHIBITS

3:15PM - 3:30PM	Session 3 Case Study – The learners select treatment options using the ARS handsets	Mark Pegram
3:30PM - 3:45PM	Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session: Is any of this a new standard of care? Should it be discussed with your patients? How can it be applied in the clinic today? Each faculty member addresses all three consensus building questions.	Discussant leader: Mark Pegram Session 3 Faculty and Audience

Session 4 - New Developments and Investigational Drugs for Treating Patients with Breast Cancer – Session Chair: Allan Lipton

3:45PM - 4:05PM	Investigational drugs treating breast cancer patients (including data from the San Antonio Symposium)	Mark Pegram
4:05PM - 4:25PM	From bone health to metastases: bone targeted agents in breast cancer	Allan Lipton
4:25PM - 4:40PM	Session 4 Case Study – The learners select treatment options using the ARS handsets	Allan Lipton
4:40PM - 4:55PM	Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session: Is any of this a new standard of care? Should it be discussed with your patients? How can it be applied in the clinic today? Each faculty member addresses all three consensus building questions.	Discussant Leader: Alan Lipton Session 4 Faculty and Audience
4:55PM - 5:00PM	CME post test and comparisons of pre-test and post-test answers	Dennis Slamon
5:00PM	ADJOURN

Educational Grants

Sincere appreciation is extended to the following companies for their generous commercial support of this educational meeting:

1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Phone: 214.866.0305 • Fax: 214.866.0311

Disclaimer: The material published on the Oncology Learning Center Web site reflect the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the Oncology Learning Center, the CME provider, or the pharmaceutical companies providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified medical or surgical oncologist, or hematologist should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any Oncology Learning Center materials. Click here for our Privacy Policy.